Proud to present PDX Pharma’s new review article in collaboration with OHSU and University of Texas MD Anderson Cancer Center. “Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials” published in Radiotherapy and Oncology.
Targeted therapies may augment the therapeutic window of radiotherapy, but toxicities from combining radiation and targeted therapy remain a concern in certain clinical contexts.
Nanomedicines providing radiation dose enhancement or tumor-targeted therapeutic delivery are being actively explored in combination with radiation.
For clinical decision-making, discussion between radiation oncologists and medical oncologists is highly encouraged to determine the potential benefits and risks of combining targeted therapies and radiation.